

Get in the KNOW
on LA Startups & Tech
XMeet the Startup That Wants To Deliver Ketamine to Your Door
David Shultz
David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.
Ketamine is on the come up in the pharmaceutical world. Once confined to nightclubs and operating rooms, the drug is quickly gaining recognition as a valuable tool for treating mental health disorders including depression and anxiety.
Amid these rising tides, Wondermed has emerged, offering telehealth consultations and, potentially, the ability to deliver the drug right to your doorstep—all while building out a virtual platform and collecting data on how to use the molecule more effectively.
At the moment, the company provides a mail order service for courses of ketamine lozenges to those who’ve been prescribed the drug along with a telehealth software bridge between doctor and patient. Wondermed currently operates in five states — California, Texas, Florida, New York and Connecticut, though it plans to expand to another eight to 10 states in the next two weeks.
In the long run however, its plans are much bigger than being a link between doctors and patients.
“We generate more than 3,000 data points on every patient that comes into the funnel, and actually receives the medication,” says co-founder & Managing Director Jose Aycart.
His company is building out its online platform to collect and analyze patient data and provide mental health support services that may be useful, regardless of whether or not a patient is taking ketamine.
These data show in granular detail how ketamine therapies work. Does the route of administration matter? Does time of day matter? What types of patients are most likely to experience positive outcomes? It’s this data that represents the biggest business opportunity for Wondermed. The specifics of the monetization are still being worked out, but Aycart says it will never sell anonymized patient data to other companies.
Wondermed is in the midst of a seed funding round, targeting $7 million by the end of the month; It’s raised $5.6 million so far.
The company makes a bit of revenue by charging patients for consultations, but in the event that a patient doesn’t wind up using Wondermed’s platform, the consultation fee is refunded. For patients who are prescribed ketamine, the company charges only as much as the drugs cost them ($249 per month, which includes four doses), so neither Wondermed nor the physicians in its employ are incentivized to over-prescribe.
The drugs themselves are supplied by Tailor Made Compounding, a pharmacy in Nicholasville, Kentucky, and Wondermed is working on additional contracts in the pipeline with several other suppliers.
. Wondermed’s transformation comes as ketamine, which has typically been restricted to use as a general anesthetic, is quickly gaining recognition as a valuable tool for treating mental health disorders like depression and anxiety.
“What I’ve found interesting is how rapidly this field has emerged,” says Steven Grant, a drug and addiction researcher who spent 25 years at the National Institute on Drug Abuse and is now retired.

Ketamine is a simple organic molecule that first gained clinical popularity in the 1960s as an anesthetic. It produces a dissociative state in patients and dulls pain. Once in the bloodstream, the molecule travels to the brain where it binds to a protein called NMDA on the surface of neurons. NMDA has a variety of jobs, but it’s best-known for its role in learning, memory, and neuroplasticity—or the brain’s ability to form new pathways between neurons.
While the research into why ketamine is such an effective treatment for depression and anxiety is ongoing, the consensus so far is that the molecule’s power comes from this ability to rewrite or rewire the brain’s circuitry. If you’ve ever had an anxiety attack or a depressive episode, it can often feel like you’re stuck in a mental loop. Ketamine, it seems, offers a way to break that loop.
“It was this idea that you're increasing your neurological connections in the brain,” says Aycart. “You have the opportunity now to spark new forms of thought, new forms of emotion, or even new ideas.”
Unlike selective serotonin reuptake inhibitors (SSRIs) and other traditional drugs used to treat depression, ketamine’s effects are fast-acting—often appearing within minutes or hours of administration—and don’t require taking the drug daily.
“It really is revolutionary, and that’s why now more than ever, people are starting to get access to it, and companies like ourselves are really trying to bring it to people as an alternative form of medicine,” says Aycart.
Grant says the rise of ketamine clinics and telehealth services like Wondermed are likely a net positive because they increase patient access to drugs patients need, but he also has reservations about how the therapies are being applied.
Many of these psychoactive drugs—especially ketamine—are intended to be used in tandem with therapy, or at least under the supervision of a trained professional. Increasing the brain’s plasticity is a valuable tool for breaking out of depressive loops, but unless a professional is there to help the patient settle into a healthier mental pattern, the full benefits may be left on the table.
Wondermed offers a variety of supplementary support and strategies along with the drugs themselves, but taking advantage of these tools is left to the patient’s discretion. Grant would like to see a larger focus on extending and expanding that auxiliary support.
The company says it’s focused on building out the platform’s nonmedicinal mental health strategies—things like breathwork, meditation, music therapy—and adding them to an app. If they can get enough people on board, the eventual plan could be to sell health insights back to patients through a subscription model or something similar. They may even patent their own psychedelic molecules in the future. But all of this is likely quite a ways out.
“What we're trying to do is very new, and the landscape yet hasn't been built out,” says Aycart.
Clarification: This story has been updated to clarify Wondermed's monthly rate for ketamine lozenges.
From Your Site Articles
- Psychedelic Therapies Are Gaining Steam as Attitudes Change - dot ... ›
- Ketamine for Depression Is Now Available by Injection - dot.LA ›
- Ketamine Clinics Are Opening Across Los Angeles - dot.LA ›
- Pasithea Opens a Chic Clinic in Beverly Hills to Administer Ketamine - dot.LA ›
- New Pasithea Ketamine Clinic In Beverly Hills - dot.LA ›
- Pasithea Opens a Ketamine Clinic In Beverly Hills - dot.LA ›
Related Articles Around the Web
David Shultz
David Shultz reports on clean technology and electric vehicles, among other industries, for dot.LA. His writing has appeared in The Atlantic, Outside, Nautilus and many other publications.
Capsida Has a New Facility To Manufacture Treatments for ALS and Friedreich’s Ataxia
06:55 AM | July 23, 2021
Photo by Keerthi Vedantam
It may just be symbolic, but the two-year-old gene therapy Capsida Biotherapeutics built its manufacturing site in the shadow of pharma giant Amgen's headquarters, a wink to its greater ambitions.
Capsida's new 15,000-square-foot manufacturing site in Thousand Oaks will be used to engineer small viral particles to treat rare diseases like ALS and Friedreich's Ataxia, both of which severely impact mobility.
It's a rare move for a company that young; most startups developing therapeutics often partner with a contract manufacturing facility that makes drugs for multiple companies. But Capsida, already a fully-integrated company that works on research and development and preclinical studies, will be able to create therapeutics at a higher rate than if they were to contract.
"We've decided that, given our platform and what we feel like we can do with capsid engineering, the speed to market and the ability to get to clinic is such that if we have our own internal capabilities, we can move faster. We can be more agile," Capsida Chief Manufacturing Officer Rayne Waller said.

Capsida's facility comes with two production suites where equipment can move flexibly (which will be useful as the company scales up, scales out or pivots), a sterile fill room to package drugs, and a large storage facility to preserve drugs in freezers. The facility will employ 40 to 50 people. Capsida is still building out a research space that will be anywhere from 20,000 to 25,000 square feet that will look into different use cases for capsid engineering — and the facility can support three to four clinical programs a year, allowing Capsida to test for a variety of use cases.
Capsida's facility is yet more proof of the impact local funding can have on keeping companies in L.A. The company announced in April it raised $140 million from Westlake Village BioPartners, a two-year-old venture capital firm founded by Amgen executives that raised one of the biggest funding rounds of 2020 in L.A and invested in several life science companies in Southern California. The firm recently built out an incubator space and office spaces for companies like Capsida to move into.
Venture capital firms like Westlake Village BioPartners are key to establishing biotech companies in L.A., according to Stephanie Hsieh, head of the Los Angeles' office for Biocom. In order to successfully pull off drug development, she said startups need need "the right investors with the sophistication and the knowledge of what it takes to really invest in biotech."
"It's super long lead times. It's a really complex product when you're talking about drugs and all that goes into it," Hsieh said.
The facility is another win for Thousand Oaks, which changed its zoning laws two years ago in a bid to accommodate more biotech companies. Capsida's facility is surrounded by medical technology facilities, including manufacturer ECA Medical Instruments, immunotherapy company Atara Biotherapeutics and pharma giant Amgen.
"We realized early on how important it is to make way for growth in the sector and to attract some of the best research companies in the world," said Thousand Oaks Mayor Claudia Bill-de la Peña.
From Your Site Articles
- Capsida Biotherapeutics Raises $140M for Its Gene Therapies - dot ... ›
- Appia Bio Aims to Offer Safer Cancer-Fighting Cell Therapies - dot.LA ›
- Capsida Partners With CRISPR Therapeutics To Treat ALS - dot.LA ›
Related Articles Around the Web
Read moreShow less
biotechmedtechalsfriendreich's ataxiathousand oaksgene therapyamgenwestlake village biopartnerscapsida biotherapeutics
Keerthi Vedantam
Keerthi Vedantam is a bioscience reporter at dot.LA. She cut her teeth covering everything from cloud computing to 5G in San Francisco and Seattle. Before she covered tech, Keerthi reported on tribal lands and congressional policy in Washington, D.C. Connect with her on Twitter, Clubhouse (@keerthivedantam) or Signal at 408-470-0776.
https://twitter.com/KeerthiVedantam
keerthi@dot.la
Swipe Less, Know More, Build Faster: LA’s AI Push
10:25 AM | November 07, 2025
🔦 Spotlight
Happy Friday LA!
This week was about AI moving from side feature to core product strategy. Tinder is testing an opt-in “Chemistry” flow that learns your interests with permission, including signals from your camera roll, to propose fewer, higher quality matches. Snap is wiring Perplexity’s conversational, source linked answers directly into Snapchat. And Rivian spun out Mind Robotics to take the industrial AI it built for its own lines to a broader market.
Tinder Bets on AI for Quality Over Quantity
Tinder is piloting Chemistry, an opt-in experience that starts with a short Q&A and, with permission, analyzes cues from your camera roll to build a richer picture of what you like. The aim is to cut through swipe fatigue by presenting a smaller set of high intent matches each day, first in New Zealand and Australia, as part of Match Group’s larger 2026 product overhaul. The pitch is relevance and control, with phased rollout and consent front and center; if engagement lifts, expect tighter loops between real world signals and match recommendations.
Snap Brings Perplexity Answers into Snapchat
Snap struck a deal with Perplexity to deliver conversational, source linked results inside Snapchat starting in early 2026, backed by a one year cash and equity package reportedly worth about 400 million dollars. Ask a question where you already spend time and get a cited answer without hopping to a mobile browser, with Snap emphasizing that Snapchat data will not train Perplexity’s models. The announcement landed alongside improving fundamentals, signaling Snap’s plan to make trustworthy answers feel native to social habits rather than a separate destination.
Rivian Spins Out Mind Robotics
Rivian formed Mind Robotics to productize the software and systems that coordinate its own manufacturing, raising roughly 110 to 115 million dollars led by Eclipse. The goal is to sell factory floor intelligence beyond vehicles, including adaptive quality control, smarter material handling, and autonomous workflows that reduce downtime. With Rivian’s headquarters in Irvine and a growing regional robotics talent base, this puts Southern California on the map for next generation industrial automation tied to the EV supply chain.
Bottom line
LA’s tech scene is pushing AI toward measurable outcomes: better match quality, faster answers with clear citations, and more efficient production. Keep an eye on the unsexy details, including privacy choices and user consent, data boundaries between partners, and how each team turns these features into monetization. That is where this week’s announcements will turn into lasting advantage.
🤝 Venture Deals
LA Companies
- Evotrex exited stealth with a $16M Pre-A round led by Xstar Capital, with Unity Ventures, Kylinhall Partners, Vision Plus Capital, and founders of Anker Innovations participating; the capital will expand engineering and speed commercialization of its first product. The California startup plans to debut what it calls the world’s first power-generating RV trailer at CES 2026, designed to provide off-grid power and help extend EV range while towing. - learn more
- Zest AI, which provides AI-driven credit underwriting and lending intelligence for banks and credit unions, closed an oversubscribed, customer-led financing round from SchoolsFirst, Members 1st, ORNL, and Truliant credit unions, with participation from Citi Ventures. The company says the round came at a higher valuation than its prior growth raise and will fund more automation across the borrower journey and a broader rollout of LuLu, its generative AI lending-intelligence platform. - learn more
- Estate Media, the social first real estate media startup co-founded by “Million Dollar Listing” star Josh Flagg, says it has surpassed $6M in revenue and closed a $1M seed round, bringing total funding to $2.65M. New investors include Tinder co-founder Justin Mateen and real estate and media figures such as Samir Mezrahi (“Zillow Gone Wild”), Tracy Tutor, and Hudson Advisory, which the company says positions it for profitability and further growth. - learn more
LA Venture Funds
- Cedars Sinai Ventures joined Amae Health’s $25M Series B, led by Altos Ventures with participation from Quiet Capital, Bling Capital, Healthier Capital, and 8VC. The company, which is building an AI enabled clinic model for severe mental illness, says the funding will accelerate nationwide clinic openings, advance its AI care platform, and support research into conditions like schizophrenia, bipolar disorder, and treatment resistant depression. Total funding now tops $50 million. - learn more
- Magnify Ventures participated in MiSalud Health’s new funding round led by IGNIA, alongside Ulu Ventures, Redwood Ventures, Amplifica Capital, and client investor Taylor Farms. MiSalud, which delivers bilingual virtual and on-site care for blue-collar workforces, says the capital will help it expand into 20 new states and add services typically offered only in person; reports peg total funding at about $18.3 million. - learn more
- Alexandria Venture Investments participated in Accipiter Biosciences’ $12.7M seed round, which was co-led by Takeda and Flying Fish Partners. The Seattle startup is developing AI-designed de novo protein therapeutics that can combine multiple mechanisms in a single molecule, and it also announced partnerships with Pfizer and Kite Pharma alongside the financing. The company says the funds will advance preclinical programs in immunology and oncology and further build out its computational design platform. - learn more
- Rebel Fund participated in Cactus’s $7M seed round alongside Wellington Management, Y Combinator, and Pelion Venture Partners. Cactus builds a 24/7 AI copilot for home service businesses that answers calls, qualifies leads, books jobs, and manages follow ups to capture after hours demand. The company says the funding will support product expansion and go to market growth in the United States. - learn more
- B Capital joined the angel round for Microtide Biotechnology (also known as Weitao Bio), which raised over RMB 100 million, led by Qiming Venture Partners. The Shanghai company, spun out from Sile Biomedicine’s in vivo CAR T platform, is developing targeted LNP delivered in vivo CAR T therapies for blood cancers and autoimmune diseases, and will use the funds to advance its first candidate and further develop its core platform. - learn more
- Patron co led Flint’s $15M Series A, with participation from the USC Viterbi School of Engineering alongside Basis Set Ventures, AME Cloud Ventures, Afore Capital, and Y Combinator. Flint builds an AI platform that helps teachers personalize K 12 learning, and the company says the funding will accelerate product development and scale the service to more schools. - learn more
- Rebel Fund participated in Freya’s $3.5M round alongside Y Combinator, 212 VC, N1 Tech, BD Partners, and others. Freya is building voice automation tools that let companies create and manage natural language voice workflows, aiming to replace brittle IVR systems with more flexible, AI powered voice agents. The company says the funding will accelerate product development and early go to market efforts. - learn more
- Regeneration.VC led Hullbot’s roughly $10.6M Series A, with participation from Climate Tech Partners, Katapult Ocean, Folklore, Trinity Ventures, Rypples, NewSouth Innovations, and Bandera Capital. The Australian startup builds autonomous hull-cleaning robots that remove biofouling to cut ship fuel use and emissions, and it plans to use the funding to ramp manufacturing, expand global service hubs, and develop larger robotic platforms. - learn more
- M13 led Teleskope’s $25M Series A, with continued participation from Primary Venture Partners and Lerer Hippeau. Teleskope builds an agentic data security platform for the AI era, and says the capital brings total funding to $32.2M to accelerate product development and scale go to market. - learn more
- SmartGateVC participated in Coherence Neuro’s $10M seed round led by Topology Ventures and Artesian, alongside Blackbird, Possible Ventures, XEIA, Jumpspace, Divergent, Spacewalk VC, and others. San Francisco based Coherence Neuro is developing a closed-loop, bi-directional neurotechnology platform to treat cancers like glioblastoma by decoding and modulating electrical signals; the funding will support its first human trials and further product development. - learn more
- Rebel Fund participated in Mecha Health’s $4.1M seed round led by Valia Ventures, alongside Y Combinator, Reach Capital, and Phosphor Capital. Mecha Health is an applied AI lab that builds foundation models for radiology which read medical images and generate fully structured reports, and the new capital supports continued development and deployment of these systems. - learn more
LA Exits
- Green Econome was acquired by VCA Green, the sustainability practice of VCA Consultants. The Los Angeles firm is known for lifecycle strategies, building performance reporting, and compliance services like ENERGY STAR, LEED, CALGreen, and Title 24; combining it with VCA Green’s energy modeling, project management, and field verification creates a single team serving both new construction and existing buildings. Marika Erdely, Green Econome’s founder, is joining VCA Green as a principal. - learn more
- InData Consulting was acquired by The 20 MSP as part of a three-company deal that also included Red Level Group and iStreet Solutions. The additions expand The 20 MSP’s footprint in California, Arizona, Michigan, and the Sacramento area, bringing its total to 44 acquisitions in about three years. The company says it sources targets from its peer group to speed integrations and reduce attrition. - learn more
- Caulipower was acquired by Urban Farmer, a Paine Schwartz Partners portfolio company, creating a vertically integrated “better for you” frozen foods platform that pairs Urban Farmer’s manufacturing with Caulipower’s nationwide brand and distribution. Caulipower will continue operating under its name, with founder Gail Becker joining Urban Farmer’s board; financial terms were not disclosed. - learn more
- StudyOS was acquired by Sitero, a technology-enabled CRO, which simultaneously launched SiteroAI to position itself as the industry’s first fully AI-powered CRO. StudyOS’s Ash clinical-trial agent will be integrated with Sitero’s Mentor eClinical suite, with Sitero projecting 20–30% efficiency gains across the trial lifecycle beginning in 2026; terms were not disclosed. - learn more
Read moreShow less
RELATEDTRENDING
LA TECH JOBS


